RESEARCH - Oral administration of type-II collagen peptide 250-270 suppresses specific cellular and humoral immune response in collagen-induced arthritis

[Guest guest]

Clin Immunol. 2007 Jan;122(1):75-84. Epub 2006 Oct 11.

Oral administration of type-II collagen peptide 250-270 suppresses

specific cellular and humoral immune response in collagen-induced

arthritis.

Zhu P, Li XY, Wang HK, Jia JF, Zheng ZH, Ding J, Fan CM.

Department of Clinical Immunology, Xijing Hospital, Fourth Military

Medical University, Xi'an 710032, Shaanxi Province, PR China.

Oral antigen is an attractive approach for the treatment of autoimmune

and inflammatory diseases. Establishment of immune markers and methods

in evaluating the effects of antigen-specific cellular and humoral

immune responses will help the application of oral tolerance in the

treatment of human diseases. The present article observed the effects

of chicken collagen II (CII), the recombinant polymerized human

collagen II 250-270 (rhCII 250-270) peptide and synthesized human CII

250-270 (syCII 250-270) peptide on the induction of antigen-specific

autoimmune response in rheumatoid arthritis (RA) peripheral blood

mononuclear cells (PBMC) and on the specific cellular and humoral

immune response in collagen-induced arthritis (CIA) and mice fed with

CII (250-270) prior to immunization with CII. In the study,

proliferation, activation and intracellular cytokine production of

antigen-specific T lymphocytes were simultaneously analyzed by

bromodeoxyuridine (BrdU) incorporation and flow cytometry at the

single-cell level. The antigen-specific antibody and antibody-forming

cells were detected by ELISA and ELISPOT, respectively. CII (250-270)

was found to have stimulated the response of specific lymphocytes in

PBMC from RA patients, including the increase expression of surface

activation antigen marker CD69 and CD25, and DNA synthesis. Mice, fed

with CII (250-270) before CII immunization, had significantly lower

arthritic scores than the mice immunized with CII alone, and the body

weight of the former increased during the study period. Furthermore,

the specific T cell activity, proliferation and secretion of

interferon (IFN)-gamma in spleen cells were actively suppressed in CII

(250-270)-fed mice, and the serum anti-CII, anti-CII (250-270)

antibody activities and the frequency of specific antibody-forming

spleen cells were significantly lower in CII (250-270)-fed mice than

in mice immunized with CII alone. These observations suggest that oral

administration of CII (250-270) can suppress the cellular and humoral

immune response in collagen-induced arthritis, and the simultaneous

analysis of antigen-specific cellular and humoral immune responses at

single-cell level will help the understanding of the oral tolerance

mechanisms in CIA and the development of innovative therapeutic

intervention for RA.

PMID: 17045846

http://www.ncbi.nlm.nih.gov/pubmed/17045846

Not an MD